Cue Biopharma is trading at $22.45, up 6.10%, with no specific catalyst established.
- No fresh company-specific announcement explaining the October 29 move was found; the investor-relations page lists its September 20 CUE-221 Phase 2 results as the latest release.
- The gain runs opposite the supplied direction for major U.S. indices, so broad-market sentiment does not clearly explain it.